Search Results

You are looking at 231 - 240 of 2,860 items for :

  • Refine by Access: All x
Clear All
Full access

HSR20-108: Treatment Patterns and Outcomes in US Adults with Metastatic Non-Small Cell Lung Cancer: A Retrospective Cohort Study of First-Line Treatments

Ashley Tabah, David Huggar, Ronda Copher, Marc Tian, and Ali McBride

real-world treatment patterns and outcomes in metastatic NSCLC patients treated with a first line (1L) therapy. Methods: A retrospective cohort analysis of IBM MarketScan@ Commercial and Medicare Supplemental Claims Databases was conducted. The

Full access

HSR21-067: What Patient-Reported Outcomes Are Being Used in Non-small Cell Lung Cancer? A Targeted Literature Review of Randomized Clinical Trials and Regulatory Labeling

Kajal Patel, Soham Shukla, Jennifer Hanlon, Kelly Bell, Laurie Eliason, and Cosmina Hogea

-reported outcome (PRO) data, an important resource in the field of oncology, has the potential to offer direct insight into the patient’s treatment experience, beyond efficacy and safety measures. Methods: A targeted literature search for PROs was performed using

Full access

HSR20-105: The Impact of Gastric Cancer Clinical Pathways Based on National Comprehensive Cancer Network Guidelines on Treatment Heterogeneity and Clinical Outcomes in the US Oncology Network

Scott Paulson, Curtis Waycaster, Bismark Baidoo, Astra M. Liepa, Anindya Chatterjee, and Lisa M. Hess

Background: It is generally assumed that adherence to clinical practice guidelines can reduce treatment variability and improve patient outcomes. Gastric cancer clinical treatment pathways were implemented in the US Oncology Network (USON) in

Full access

CLO21-022: Efficacy and Safety Outcomes With Therapies for Stage I-III Merkel Cell Carcinoma (MCC): A Systematic Literature Review

David Miller, Roberto Palencia, Ting Yu, Amrita Sandhu, Sarah Webb, Tom Blaikie, and Murtuza Bharmal

studies with efficacy and safety outcomes with relevant interventions in patients with stage I-III MCC. The review included monotherapies or combinations of pharmacological treatments, radiotherapy (RT), chemotherapy (CT), and surgery (SUR). Adjuvant (adj

Full access

BPI24-021: Impact of Social Determinants (SDOH) on Surgery and Patient Outcomes in Early-Stage Non–Small Cell Lung Cancer (eNSCLC)

Atharv Sharma, Manu Prasad, Tianyuan Hu, Arunav Saikia, Prabhakar Gaur, Venkata Sai Sumanth Pulluri, and Stuti Jha

Background: Disparities in eNSCLC treatment related to SDOH factors are a significant concern. This study used real-world data to assess how SDOH impacts patient outcomes and the time taken to receive surgery. Method: The study included 18

Full access

Mobile Technology-Based (mLearning) Intervention to Enhance Breast Cancer Clinicians' Communication About Sexual Health: A Pilot Trial

Jennifer Barsky Reese, Lauren A. Zimmaro, Sharon L. Bober, Kristen Sorice, Elizabeth Handorf, Elaine Wittenberg, Areej El-Jawahri, Mary Catherine Beach, Antonio C. Wolff, Mary B. Daly, Brynna Izquierdo, and Stephen J. Lepore

communication skills development, 22 – 24 and social cognitive theory, which emphasizes individuals’ beliefs (ie, self-efficacy and outcome expectancies) as critical processes underlying successful behavioral interventions. 22 , 25 – 28 We adapted the

Full access

BIO22-031: Potential Implications in Immunotherapy and Prognostic Outcomes of Non-Small Cell Lung Cancer for Computational Recognition of lncRNA Signature of Tumor-Associated Neutrophils

Zhuoran Tang, Chunyu Li, Peixin Chen, Haoyue Guo, Jinpeng Shi, Yingying Pan, Qi Wang, and Caicun Zhou

characteristics. The risk score was determined using LASSO Cox regression analysis. Meanwhile, we named this risk score as “TANlncSig”. TANlncSig was able to distinguish between better and worse survival outcomes in various patient datasets independently of other

Full access

Additional Abstracts from the NCCN 21st Annual Conference: Advancing the Standard of Cancer Care™

interventions to minimize distress and improve patient quality of life. AB2016-29. Treatment Outcomes in Patients With Metastatic Neuroendocrine Tumors: Retrospective Analysis of a Community Oncology Database Maxine D. Fisher, PhD a ; Sonia Pulgar, MPH b

Full access

HSR23-120: Real-World Observations Show Beneficial Outcomes in Patients With NSCLC Treated With Pembrolizumab for More Than 2 Years

Lucio Gordan, Rushir Choksi, Daniel Petro, Melissa Johnson, Anupama Vasudevan, Sandy English, Marielle Fares, Heidi Gidley, Teena Sura, and Prateesh Varughese

at patient outcomes after >2 years of P treatment. The aim of this real-world study was to evaluate patient outcomes related to P use for >2 years in patients with stage IV NSCLC. Using the de-identified Precision Q database, authors evaluated

Full access

HSR22-180: Real-World Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy in BRAF+ Cutaneous Melanoma Patients Treated in the Adjuvant Setting

Sanjay Chandrasekaran, You-Li Ling, Jackson Tang, Deborah Norton, and Rohan Shah

use in the real-world setting is scarce. Objective : To examine treatment patterns and outcomes among BRAF+ cutaneous melanoma patients treated with adjuvant IO or DT in the United States. Methods: This was a retrospective cohort study using